Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.

Virstatin is a small molecule that inhibits Vibrio cholerae virulence regulation, the causative agent for cholera. Here we report the interaction of virstatin with human serum albumin (HSA) using various biophysical methods. The drug binding was monitored using different isomeric forms of HSA (N for...

Full description

Bibliographic Details
Main Authors: Tanaya Chatterjee, Aritrika Pal, Sucharita Dey, Barun K Chatterjee, Pinak Chakrabarti
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3359307?pdf=render
id doaj-2ecea4e6a70a444dbc227740afead8c1
record_format Article
spelling doaj-2ecea4e6a70a444dbc227740afead8c12020-11-25T01:58:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0175e3746810.1371/journal.pone.0037468Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.Tanaya ChatterjeeAritrika PalSucharita DeyBarun K ChatterjeePinak ChakrabartiVirstatin is a small molecule that inhibits Vibrio cholerae virulence regulation, the causative agent for cholera. Here we report the interaction of virstatin with human serum albumin (HSA) using various biophysical methods. The drug binding was monitored using different isomeric forms of HSA (N form ∼pH 7.2, B form ∼pH 9.0 and F form ∼pH 3.5) by absorption and fluorescence spectroscopy. There is a considerable quenching of the intrinsic fluorescence of HSA on binding the drug. The distance (r) between donor (Trp214 in HSA) and acceptor (virstatin), obtained from Forster-type fluorescence resonance energy transfer (FRET), was found to be 3.05 nm. The ITC data revealed that the binding was an enthalpy-driven process and the binding constants K(a) for N and B isomers were found to be 6.09×10(5 )M(-1) and 4.47×10(5) M(-1), respectively. The conformational changes of HSA due to the interaction with the drug were investigated from circular dichroism (CD) and Fourier Transform Infrared (FTIR) spectroscopy. For 1:1 molar ratio of the protein and the drug the far-UV CD spectra showed an increase in α- helicity for all the conformers of HSA, and the protein is stabilized against urea and thermal unfolding. Molecular docking studies revealed possible residues involved in the protein-drug interaction and indicated that virstatin binds to Site I (subdomain IIA), also known as the warfarin binding site.http://europepmc.org/articles/PMC3359307?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Tanaya Chatterjee
Aritrika Pal
Sucharita Dey
Barun K Chatterjee
Pinak Chakrabarti
spellingShingle Tanaya Chatterjee
Aritrika Pal
Sucharita Dey
Barun K Chatterjee
Pinak Chakrabarti
Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.
PLoS ONE
author_facet Tanaya Chatterjee
Aritrika Pal
Sucharita Dey
Barun K Chatterjee
Pinak Chakrabarti
author_sort Tanaya Chatterjee
title Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.
title_short Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.
title_full Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.
title_fullStr Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.
title_full_unstemmed Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.
title_sort interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Virstatin is a small molecule that inhibits Vibrio cholerae virulence regulation, the causative agent for cholera. Here we report the interaction of virstatin with human serum albumin (HSA) using various biophysical methods. The drug binding was monitored using different isomeric forms of HSA (N form ∼pH 7.2, B form ∼pH 9.0 and F form ∼pH 3.5) by absorption and fluorescence spectroscopy. There is a considerable quenching of the intrinsic fluorescence of HSA on binding the drug. The distance (r) between donor (Trp214 in HSA) and acceptor (virstatin), obtained from Forster-type fluorescence resonance energy transfer (FRET), was found to be 3.05 nm. The ITC data revealed that the binding was an enthalpy-driven process and the binding constants K(a) for N and B isomers were found to be 6.09×10(5 )M(-1) and 4.47×10(5) M(-1), respectively. The conformational changes of HSA due to the interaction with the drug were investigated from circular dichroism (CD) and Fourier Transform Infrared (FTIR) spectroscopy. For 1:1 molar ratio of the protein and the drug the far-UV CD spectra showed an increase in α- helicity for all the conformers of HSA, and the protein is stabilized against urea and thermal unfolding. Molecular docking studies revealed possible residues involved in the protein-drug interaction and indicated that virstatin binds to Site I (subdomain IIA), also known as the warfarin binding site.
url http://europepmc.org/articles/PMC3359307?pdf=render
work_keys_str_mv AT tanayachatterjee interactionofvirstatinwithhumanserumalbuminspectroscopicanalysisandmolecularmodeling
AT aritrikapal interactionofvirstatinwithhumanserumalbuminspectroscopicanalysisandmolecularmodeling
AT sucharitadey interactionofvirstatinwithhumanserumalbuminspectroscopicanalysisandmolecularmodeling
AT barunkchatterjee interactionofvirstatinwithhumanserumalbuminspectroscopicanalysisandmolecularmodeling
AT pinakchakrabarti interactionofvirstatinwithhumanserumalbuminspectroscopicanalysisandmolecularmodeling
_version_ 1724970784122732544